11--22--04

Attorney's Docket No.: 16743-003001 / 12A-920716



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 10/705,245

Art Unit : 1614

Examiner : Unknown

Filed: November 10, 2003

Title : RISK ASSESSMENT FOR ADVERSE DRUG REACTIONS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL NFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

Articles

- 1. Chung, W.H., et al. (2004). Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 428(6982):486.
- 2. Gumperz, J.E., et al. (1995). The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med. 181(3):1133-1144.
- 3. Gut, J. (2002). Severe adverse drug reactions and theragenomics. Business Briefing Pharmatech. Retrieved from the Internet: <u>URL: http://therastrat.com/downloads/Gut_2002_Servere_Adverse_Drug_Reactions.pdf</u>> retrieved on 2004-10-01.
- 4. Hildesheim, A., et al. (2002). Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst. 94(23):1780-1789.
- 5. Mallal, S. et al. (2002). Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 359(9308):727-732.

CERTIFICATE	OF MAILING BY EXPRESS MAIL
Express Mail Label No	EV584750764US
	November 18, 2004
Date of Deposit	November 18, 2004

Applicant: Chen, et al. Attorney's Docket No.: 16743-003001 / 12A-920716

Serial No.: 10/705,245

Filed: November 10, 2003

Page : 2 of 3

6. Nassif, A., et al. (2002). Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol. 118(4):728-733.

- 7. Pirmohamed, M., and Park, B.K. (2003). Adverse drug reactions: back to the future. Br J Clin Pharmacol. 55(5):486-492.
- 8. Romphruk, A., et al. (2003). HLA-B*15 subtypes in the population of north-eastern Thailand. Eur J Immunogenet. 30(2):153-158.

These documents are being submitted before a first Office Action on the merits, therefore no fee is required under 37 C.F.R. § 1.97(b). In the event an Office Action is mailed by the United States Patent and Trademark Office prior to receipt of this Information Disclosure Statement, Applicants hereby make the statement specified in 37 C.F.R. §1.97(e) that each document contained herein was first cited in the International Search Report for the corresponding PCT application (PCT/US2004/019435) within three (3) months of the filing date of this Supplemental Information Disclosure Statement. Therefore, no fee is required under 37 C.F.R. § 1.97(c). A copy of this International Search Report is also enclosed herewith.

For the purpose of patent term adjustment, Applicants also wish to point out that this Supplemental Information Disclosure Statement is being filed within 30 days of receipt of the aforementioned International Search Report by Applicants or Applicants' representatives.

By citing the above references, Applicants do not acquiesce or admit that any of these documents is "prior art" under 35 U.S.C. Applicants specifically reserve the right, where appropriate, to antedate any of the cited documents by an appropriate showing under 37 C.F.R. §1.131, §1.604, §1.608 or any other suitable means.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Applicant : Chen, et al. Attorney's Docket No.: 16743-003001 / 12A-920716

Serial No.: 10/705,245

Filed: November 10, 2003

Page : 3 of 3

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: Nov. 18, 2004

Ping F. Hwung Reg. No. 44164

Fish & Richardson P.C. 500 Arguello Street, Suite 500 Redwood City, California 94063 Telephone: (650) 839-5070 Facsimile: (650) 839-5071

50247346.doc

10/705,245

VOW	1 8 2004 B
E "	Substitute from PTO-1449 (Modified)
Wes	EADE
	Supplemental Inform
) by
	()

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 16743-003001 / 12A-920716 Application No.

tal Information Disclosure Statement
by Applicant
(Use several sheets if necessary)

Applicant

Chen, et al.

(37 CFR §1.98(b))

Filing Date
November 10, 2003

Group Art Unit 1614

U.S. Patent Documents

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner	Desig.	Document	Publication	Country or			Trans	lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	AD	_						
	AE							
	AF							

Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.			
Initial	ID	Document		
	AG	Chung, W.H., et al. (2004). Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 428(6982):486.		
		Gumperz, J.E., et al. (1995). The Bw4 public epitope of HLA-B molecules confers		
	AH	reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med. 181(3):1133-1144.		
		Gut, J. (2002). Severe adverse drug reactions and theragenomics. Business Briefing		
	AI	Pharmatech. Retrieved from the Internet: <u>URL: http://therastrat.com/downloads/</u>		
		Gut 2002 Servere Adverse Drug Reactions.pdf> retrieved on 2004-10-01.		
		Hildesheim, A., et al. (2002). Association of HLA class I and II alleles and extended		
	AJ	haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst.		
		94(23):1780-1789.		
		Mallal, S. et al. (2002). Association between presence of HLA-B*5701, HLA-DR7, and		
	AK	HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.		
		Lancet. 359(9308):727-732.		
	AL	Nassif, A., et al. (2002). Drug specific cytotoxic T-cells in the skin lesions of a patient with		
	AL	toxic epidermal necrolysis. J Invest Dermatol. 118(4):728-733.		
	AM	Pirmohamed, M., and Park, B.K. (2003). Adverse drug reactions: back to the future.		
	Alvi	Br J Clin Pharmacol. 55(5):486-492.		
	AN	Romphruk, A., et al. (2003). HLA-B*15 subtypes in the population of north-eastern		
	AIN	Thailand. Eur J Immunogenet. 30(2):153-158.		

Examiner Signature	Date Considered				
	Date Considered				
1					
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with					
	or an extraordization and not exhibiteled. Include copy of this form what				
next communication to applicant.					